Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
申请人:Agouron Pharmaceuticals, Inc.
公开号:US20040034078A1
公开(公告)日:2004-02-19
Compounds of formula I are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used in combination with cytotoxic agents and/or radiation.
1